TruScreen Group Ltd (ASX:TRU)’s Juliet Hull gives Proactive’s Elisha Newell insight into the company’s history and reason for being. The interim CEO explains the accurate, much more gentle real-time screening solution for cervical cancer. This solution is considered a primary screening tool and is an AI-enabled device that can detect precancerous and cancerous cervical changes via optical and electrical measurements of cervical tissue. The company targets lower to middle income countries, as over 80% of cervical cancer is in those countries which don’t have the infrastructure, treatment history or survival rates of countries like Australia or New Zealand. Hull discusses the experience of the board and its short- and long-term plans, which are to rapidly grow in the areas it already has presence and to move into new areas such as India, where there are growing markets.
TruScreen brings real time AI solutions to cervical cancer treatment
